** Shares of Mesoblast MSB.AX fall as much as 9.3% to A$2.55, their largest intraday pct loss since Dec 20
** Stock hits lowest level since Dec 24
** The drug developer completes private placement to raise A$260 mln ($160.73 mln)
** Placement issue price at A$2.5 per share, representing an 11% discount to stock's last close
** Co says funds to be used for the U.S. commercial launch of its Ryoncil therapy for the treatment of graft-versus-host disease, among others
** Stock down 15.2% YTD, including current session's moves
($1 = 1.6176 Australian dollars)
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。